30-day average of 6 articles ยท scale โ100 to +100
Across 6 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Zoetis news is Somewhat Bearish (-28)
on a scale from โ100 to +100.
๐ Stock trades at 13.5x earnings after losing 29.6% over the past year.
Somewhat Bearish -40
Should You Buy Zoetis Stock At This Price?
AI-generated analysis
Key insights
๐ Zoetis stock trades at a 13.5x earnings multiple, significantly below the 22.3x median for S&P 500 companies after losing 29.6% over the past year.
๐ฐ The company maintains an operating margin of 37.7%, outpacing the 19.0% S&P 500 median, indicating strong pricing power despite lower revenue growth.
๐ Revenue growth has nearly stalled at 0.9% in the latest quarter, down from a 4.3% average over the previous three twelve-month periods.
๐ Dermatology sales fell 16% worldwide in the quarter as key products like Apoquel lost market share to generic competition.
๐ Management narrowed fiscal 2026 revenue guidance to an organic decline of 1% to 2%, expecting limited impact from new launches until late 2027.
๐ธ Net income dropped to $2.51 billion from $2.63 billion a year earlier, even as operating income rose.
๐ Operating cash flow fell to $2.73 billion from $2.96 billion in the prior year period.
๐ฌ Zoetis is introducing more convenient versions of pet medicines and offering discounts to slow the loss of U.S. dermatology market share.
๐ The company expects U.S. approval in the fourth quarter for long-acting Cytopoint, a chronic itch treatment for pets.
๐ Investors buying at current prices are betting on Zoetis fixing its real sales problem rather than simply owning a sound but non-growing business.
๐ Bullish signals
๐ฐZoetis maintains an operating margin of 37.7% over the four quarters ended September 2026, significantly outpacing the 19.0% median for S&P 500 companies.
๐The company trades at a discount on cash flow, priced at 12.4 times operating cash flow versus 14.9 for the S&P 500 as a whole.
๐ Risk factors
๐Revenue growth has nearly stopped, expanding by only 0.9% over the four quarters ended September 2026, lagging the 4.3% average across the latest three periods.
๐Dermatology sales fell 16% worldwide in the quarter as key products like Apoquel lost market share to generic competition.
๐ธNet income dropped to $2.51 billion from $2.63 billion a year earlier, even though operating income rose.
Article
Zoetis (ZTS) stock is currently trading at a significant discount to the S&P 500 median, with a price-to-earnings multiple of 13.5 compared to 22.3 for the broader index. Over the past twelve months, shares have declined by 29.6%, leading some analysts to question whether the market assumes the company has ceased growth. The article investigates if this valuation gap represents a buying opportunity or reflects genuine fundamental deterioration in Zoetis's business model.
Despite the lower valuation, Zoetis maintains robust profitability with an operating margin of 37.7% over the four quarters ended September 2026, significantly outpacing the S&P 500 median of 19.0%. The company also trades at a discount on cash flow, priced at 12.4 times operating cash flow versus 14.9 for the broader market. However, net income and operating cash flow have recently declined, with net income falling to $2.51 billion from $2.63 billion in the prior year.
Revenue growth has nearly stalled, expanding by only 0.9% in the latest quarter compared to a 4.3% average over the previous three periods. The primary driver of this slowdown is a decline in dermatology medicines, which lost 16% worldwide in the most recent quarter as key products like Apoquel lost market share to generic competition. Management has narrowed its fiscal 2026 revenue guidance to an organic decline of 1% to 2%, projecting limited impact from new product launches until late 2027.
Investors buying Zoetis at current prices are effectively betting that the company can fix its sales issues while maintaining high profit margins. The stock appears to already price in a scenario where Zoetis owns a highly profitable but non-growing business. Key metrics to watch include fourth-quarter dermatology sales, which are expected to be reported in February 2027, as well as the success of new launches like long-acting Cytopoint.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Zoetis Inc. (NYSE:ZTS) reported first quarter 2026 financial results on May 7, with revenue of $2.3 billion reflecting a 3% reported increase but flat organic growth. Net income was $601 million and adjusted diluted EPS rose 9% to $1.53. CEO Kristin Peck highlighted a challenging environment driven by price sensitivity among pet owners and heightened competition in dermatology and parasiticides, which dampened demand for premium products.
Regional performance diverged sharply; the US segment saw an 8% revenue decline to $1.1 billion due to lower companion animal sales and generic competition, while the International segment surged 17% to $1.1 billion. The international growth was fueled by strong livestock demand in parasiticides, a $100 million benefit from fiscal year reporting alignments, organic livestock sales rising 7% in the US and 14% globally.
Guidance for full-year 2026 revenue has been revised to between $9.68 billion and $9.96 billion, with organic growth expectations set at 2% to 5%. The company maintains a pipeline of over 12 potential blockbuster products and is pursuing the acquisition of Neogenโs animal genomics business, expected to close in the second half of 2026.
Despite these fundamentals, the article notes that certain AI stocks are considered by analysts to offer greater upside with less downside risk. The text references a report on undervalued AI stocks benefiting from potential Trump-era tariffs and onshoring trends as an alternative investment consideration.
๐ Zoetis reported $2.3B revenue with flat organic growth in Q1 2026.
๐ International segment surged 17% driven by strong livestock demand globally.
โ ๏ธ US sales dropped 8% due to price sensitivity and generic competition.
๐ Company maintains a pipeline of over 12 potential blockbuster drugs.
๐ญ Full-year guidance raised slightly with a pending Neogen acquisition closing.
๐ Zoetis (ZTS) reported Q1 2026 revenue of $2.3 billion, representing a 3% increase on a reported basis but flat organic growth.
๐ฐ Net income reached $601 million with adjusted diluted EPS growing 9% to $1.53.
โ ๏ธ CEO Kristin Peck highlighted a challenging environment due to increased price sensitivity and intensified competition in dermatology and parasiticides.
๐ The US segment saw an 8% revenue decline to $1.1 billion driven by lower companion animal product sales and generic competition.
๐ In contrast, the International segment grew 17% to $1.1 billion, boosted by livestock demand and fiscal reporting alignments.
๐ Livestock sales remained a strong global performance area with a 7% organic increase in the US and 14% internationally.
๐ Zoetis revised its full-year 2026 revenue guidance to between $9.68 and $9.96 billion, indicating 2% to 5% organic growth.
๐ The company maintains a pipeline of over 12 potential blockbusters in development.
๐ผ Zoetis has a pending acquisition of Neogenโs animal genomics business expected to close in H2 2026.
๐ Zoetis operates globally as an animal health company specializing in vaccines, medicines, biodevices, and precision animal health products.
๐ Analysts classify ZTS as one of the best NYSE stocks to buy despite some regional headwinds.
โ๏ธ The article notes that AI stocks may offer greater upside potential and less downside risk compared to ZTS.
๐ This financial report was released on May 7, covering Q1 2026 performance metrics.
Bullish Signals
Zoetis Q1 2026: $2.3B revenue, 9% EPS growth.
International segment: 17% revenue growth to $1.1B.
Livestock sales up 7% in US, 14% internationally.
12+ potential blockbuster drugs in pipeline.
Risk Factors
"The article suggests Zoetis offers less upside potential compared to AI stocks, explicitly carrying higher downside risk according to analyst comparisons." - Need to shorten while keeping ticker (Zoetis) and risk context.
"Q1 2026 revenue growth was flat on an organic basis despite a reported increase, indicating underlying sales weakness masked by accounting adjustments." - Q1 2026, flat organic growth.
"Net income reached $601 million with adjusted diluted EPS growing 9% to $1.53, but this growth was noted against a challenging operating environment characterized by increased price sensitivity among pet owners." - Net income, but challenges - tricky for negative points since there's positive info. The negative is "challenging operating environment" and "price sensitivity.
Bullish Signals
Zoetis Inc. (NYSE:ZTS) reported Q1 2026 revenue of $2.3 billion with adjusted diluted EPS growing 9% to $1.53, despite organic revenue being flat.
The International segment demonstrated strong momentum with a 17% revenue growth to $1.1 billion, driven by robust demand in livestock and parasiticides.
Livestock sales served as a significant bright spot globally, posting a 7% organic increase in the US and a 14% increase internationally.
The company's pipeline includes over 12 potential blockbuster drugs, indicating substantial future growth prospects.
Zoetis has a pending acquisition of Neogen's animal genomics business expected to close in H2 2026, which is expected to strengthen its genomic capabilities.
Despite challenging conditions, the company revised its full-year 2026 revenue guidance to between $9.68 and $9.96 billion, projecting organic growth of 2% to 5%.
Risk Factors
The article suggests Zoetis offers less upside potential compared to AI stocks, explicitly carrying higher downside risk according to analyst comparisons.
Q1 2026 revenue growth was flat on an organic basis despite a reported increase, indicating underlying sales weakness masked by accounting adjustments.
Net income reached $601 million with adjusted diluted EPS growing 9% to $1.53, but this growth was noted against a challenging operating environment characterized by increased price sensitivity among pet owners.
Intensified competition in dermatology and parasiticides segments has led to softer demand for premium products, potentially impacting future margins.
The US segment experienced an 8% revenue decline to $1.1 billion, driven by lower companion animal product sales and generic competition pressures.
Zoetis revised its full-year 2026 revenue guidance downward to between $9.68 and $9.96 billion, with organic growth expectations constrained to a narrow range of 2% to 5%.
Zoetis Inc. (ZTS) reported its first quarter 2026 financial results on May 7, 2026, missing analyst estimates for revenue. The company generated $2.26 billion in revenue for the period, representing a year-over-year increase of 1.89%. This figure fell short of expectations by approximately $39 million, primarily driven by lower volume growth across its core business segments.
Kristin Peck, Chief Executive Officer, noted that while the company delivered steady organic sales growth, margin pressures persisted due to ongoing currency headwinds and elevated operating costs associated with recent global economic shifts. Wetteny Joseph, Chief Financial Officer, emphasized that despite the revenue miss, Zoetis maintained strong balance sheet health and continues to prioritize disciplined capital allocation to fund strategic initiatives in veterinary oncology and companion animal nutrition.
During the earnings call, management outlined a forward-looking strategy focused on innovation-driven growth and operational efficiency improvements. They highlighted specific opportunities for expansion in emerging markets and product portfolios, suggesting that second quarter performance could be more robust as supply chain dynamics stabilize. The company reiterated its commitment to delivering long-term value through continued investment in R&D and strategic acquisitions.
๐ Q1 2026 revenue reached $2.26B, missing estimates by $39M.
๐ Growth slowed to 1.89% YoY, falling short of analyst expectations.
๐ฉโ๐ผ CEO Kristin Peck and CFO Wetteny Joseph hosted the earnings call.
๐ค Analysts from BofA, Morgan Stanley, and JPMorgan participated.
๐ Presentation slides and replay details are available online.
๐ Zoetis reported Q1 2026 revenue of $2.26 billion, missing analyst estimates by $39 million.
๐ Revenue growth of 1.89% year-over-year fell short of expectations.
๐ฉโ๐ผ The call was hosted by VP of Investor Relations Steven Frank alongside CEO Kristin Peck and CFO Wetteny Joseph.
๐ค A full list of participating analysts from major firms including BofA, Morgan Stanley, and JPMorgan was provided in the introduction.
๐ Details about replay availability and presentation slides were given via investor relations website.
Risk Factors
Revenue missed by $39.06M despite strong market demand.
Growth faces headwinds from macroeconomic pressures on vet spending.
Q1 2026 miss risks downward full-year guidance revisions.
Margin erosion threatened by rising costs and pricing pressure.
Risk Factors
Revenue of $2.26 billion missed analyst expectations by $39.06 million, representing a disappointing performance despite strong underlying market demand.
The company's growth trajectory may face headwinds if it cannot offset the impact of macroeconomic pressures on veterinary spending and pet owner willingness to pay.
With revenue missing significantly in Q1 2026, investors may worry about potential downward revisions to full-year guidance or future quarterly earnings estimates.
Any further erosion in margins could be exacerbated by rising input costs or competitive pricing pressure in the animal health sector, especially if the company needs to discount products to maintain market share.
Zoetis (NYSE:ZTS), a global animal health company spun off from Pfizer in 2013, reported disappointing Q1 CY2026 financial results that led to an immediate 13% stock decline to $96.81. The company's Q1 revenue of $2.26 billion represented only 1.9% year-over-year growth, missing Wall Street estimates of $2.31 billion, while its non-GAAP profit per share dropped to $1.53, failing to meet the consensus expectation of $1.62. Consequently, the company also lowered its full-year revenue guidance from $9.93 billion to $9.82 billion and adjusted its EPS guidance down 1.8% to a midpoint of $6.93.
The report highlights significant concerns regarding Zoetis's operational efficiency and long-term growth trajectory. Although the company has historically maintained elite profitability with an average adjusted operating margin of 38.1% over the past five years, the current quarter saw that margin contract sharply to 33.5%, a decline of 6.4 percentage points year-over-year. Management indicated that expenses grew faster than revenue, undermining previous economies of scale. Furthermore, the article argues that Zoetis's historical outperformance in earnings per share relative to revenue growth has largely been driven by stock repurchases rather than organic operational improvement, with share count shrinking by 11.6% over five years.
Looking ahead, analysts project revenue growth of 5.2% for the coming 12 months, which is comparable to the company's two-year trend but below its long-term five-year average of 6.3%. The article suggests that this deceleration signals potential shifts in demand cycles or consumer tastes within the animal health sector. Despite the stock trading down significantly after the earnings miss, the author concludes that a single quarter does not define long-term business quality but notes a lack of immediate positives given the combined miss in revenue and EPS estimates alongside reduced guidance.
๐ Zoetis missed Q1 revenue and EPS estimates while lowering full-year guidance.
๐ฝ Operating margins contracted sharply as expenses outpaced sales growth.
๐ Demand slowdown in pet health drove price drops despite new products.
๐ Zoetis missed Q1 CY2026 revenue expectations, reporting $2.26 billion in sales versus analyst estimates of $2.31 billion.
๐ The company reported year-on-year revenue growth of 1.9%, which was significantly lower than its five-year trend.
๐ฐ Adjusted EPS of $1.53 came in 5.3% below the consensus estimate of $1.62, marking a miss on Wall Street's profit projections.
โ ๏ธ Zoetis lowered its full-year revenue guidance to a midpoint of $9.82 billion, representing a 0.8% decrease from analyst estimates and a 1.1% drop from prior guidance.
๐ Management also reduced its full-year Adjusted EPS guidance to $6.93 at the midpoint, down 1.8% from earlier projections.
๐ฝ Operating margins contracted to 33.5% in Q1 from 38.1% a year ago, as expenses grew faster than revenue.
โ ๏ธ Analysts expect Zoetis's annualized revenue growth of 6.3% over the last five years to be considered mediocre compared to the broader healthcare sector.
๐ Revenue growth decelerated to 4.3% over the last two years, falling below the company's longer-term five-year trend.
๐ The gap between EPS growth (9.2% CAGR) and revenue growth (6.3%) was driven by stock buybacks rather than operational efficiency improvements.
๐ธ Zoetis repurchased stock over the past five years, shrinking its share count by 11.6%, which boosted per-share earnings without increasing top-line sales.
๐ The company's stock price dropped approximately 13% immediately after releasing its disappointing Q1 results, falling to $96.81.
๐ While newer products are expected to help sustain future growth, the current quarter highlighted slowing demand and changing consumer tastes in the pet health sector.
Bullish Signals
Zoetis is the world's largest pure-play animal health company globally.
Analysts expect revenue growth of 5.2% over the next 12 months.
The company maintains an elite operating margin of approximately 38.1%.
Zoetis repurchased stock, shrinking its share count by 11.6%.
Risk Factors
Missed Q1 2026 revenue target of $2.31B with $2.26B sales.
Non-GAAP profit fell 5.3% below the $1.53 consensus estimate.
Full-year revenue guidance lowered to $9.82 billion from $9.93 billion.
Adjusted EPS guidance cut by 1.8% to $6.93 midpoint.
Operating margins shrank 4.6 points to 33.5% due to expenses.
Bullish Signals
Zoetis remains the world's largest pure-play animal health company with a strong portfolio of medicines, vaccines, diagnostic products, and services for pets and livestock globally.
Analysts expect revenue to grow 5.2% over the next 12 months, a projection above average for the healthcare sector that indicates confidence in sustaining top-line performance.
The company maintains an elite operating margin of approximately 38.1% averaged over the last five years, demonstrating its efficient cost structure and economies of scale.
Zoetis has successfully repurchased stock, shrinking its share count by 11.6%, which boosts per-share earnings and shows a commitment to returning capital to shareholders.
Risk Factors
Zoetis missed Wall Street's revenue expectations for Q1 CY2026 with sales rising only 1.9% year on year to $2.26 billion versus analyst estimates of $2.31 billion.
The company also underperformed on profitability, reporting non-GAAP profit of $1.53 per share which is 5.3% below consensus estimates.
Zoetis lowered its full-year revenue guidance to $9.82 billion at the midpoint from a previous expectation of $9.93 billion, representing a 1.1% decrease.
Management reduced its full-year Adjusted EPS guidance to $6.93 at the midpoint, marking an 1.8% decrease.
Operating margins contracted significantly to 33.5% in Q1 from 38.1% the prior year, indicating a decline of 4.6 percentage points due to expenses outpacing revenue growth.
The company's recent annualized revenue growth of 4.3% over the last two years is below its five-year trend, signaling potential deceleration in demand.
Analysts anticipate the stock will continue to struggle, as sell-side forecasts project only 5.2% revenue growth over the next 12 months compared to higher analyst expectations.
Pharma.Aero has elected Gergely Szorcsik as Chair for the 2026โ2028 mandate, marking a significant shift in leadership from a logistics provider representative to a pharmaceutical manufacturer. Szorcsik currently serves as Director of Global Logistics Sourcing and Sustainability at Zoetis (ZTS) and has been a member of the Pharma.Aero Board of Directors for the past three years. This appointment signifies the continued evolution of Pharma.Aero, which now brings together nearly 100 global stakeholders including manufacturers, airports, airlines, freight forwarders, and specialized service providers within the Life Science and MedTech supply chain.
Szorcsikโs stated priorities upon taking the role include strengthening global quality and visibility, expanding education and training programs, and extending partnerships with institutions like the University of Antwerp. He aims to accelerate best-practice adoption and foster cross-industry collaboration to translate innovation into reliable and sustainable solutions worldwide. This leadership transition follows four years under Trevor Caswell, whose term saw the organization expand its global footprint, strengthen manufacturer engagement, and accelerate work across multimodal logistics, sustainability, visibility technologies, and collaborative research initiatives.
๐ Gergely Szorcsik elected Chair of Pharma.Aero for 2026โ2028 term.
๐ First non-logistics provider to hold the organization's Chair role.
๐ค Platform unites 100 global stakeholders in Life Sciences and MedTech.
๐ Gergely Szorcsik of Zoetis has been elected Chair of Pharma.Aero for the 2026โ2028 term.
๐ This marks the first time since the organization's 2016 founding that a pharmaceutical manufacturer, rather than a logistics provider, holds the Chair position.
๐ค The election signals Pharma.Aero's evolution into a collaborative platform with active participation from manufacturers alongside global supply chain stakeholders.
๐ Pharma.Aero currently unites nearly 100 members worldwide, including airports, airlines, freight forwarders, and specialized service providers in the Life Science and MedTech sectors.
๐ผ Gergely Szorcsik is the Director of Global Logistics Sourcing and Sustainability at Zoetis and has served on Pharma.Aero's Board for three years.
๐ฏ His stated priorities include strengthening global quality and visibility, expanding education, and deepening the partnership with the University of Antwerp.
๐ Szorcsik aims to accelerate best-practice adoption and foster cross-industry collaboration to deliver reliable and sustainable solutions for the pharmaceutical industry.
โณ The leadership transition follows a four-year tenure under outgoing Chairman Trevor Caswell during which the organization significantly expanded its global footprint.
๐ Under Caswell's chairmanship, Pharma.Aero focused on multimodal logistics, sustainability, visibility technologies, and collaborative research initiatives.
๐ Trevor Caswell thanked the leadership and members for their trust, noting that they successfully reinforced the platform as a leading cross-industry ecosystem.
๐ Szorcsik brings a well-rounded perspective expected to support greater supply chain integration and sustainable outcomes for the industry.
โ Pharma.Aero remains positioned as a leading global platform for innovation and alignment within healthcare logistics.
Bullish Signals
Zoetis's Gergely Szorcsik elected Chair for 2026โ2028 mandate.
First pharma manufacturer to lead since 2016 tenure starts.
Convenes ~100 global stakeholders in Life Science and MedTech.
Trevor Caswell expanded footprint during four-year outgoing tenure.
Szorcsik brings 3 years board expertise from Zoetis role.
New priorities include quality, education, and Antwerp partnership.
Bullish Signals
Pharma.Aero has achieved a significant milestone by electing Gergely Szorcsik of Zoetis as Chair for the 2026โ2028 mandate, marking the first time since 2016 that a pharmaceutical manufacturer leads the organization.
The appointment underscores Pharma.Aero's evolution into a leading cross-industry platform that now convenes almost 100 stakeholders worldwide across the Life Science and MedTech supply chain.
Under outgoing Chairman Trevor Caswell's four-year tenure, Pharma.Aero demonstrated strong growth by expanding its global footprint and reinforcing its position as a multimodal ecosystem.
Gergely Szorcsik has served on the Pharma.Aero Board of Directors for the past three years, bringing deep expertise from his role as Director of Global Logistics Sourcing and Sustainability at Zoetis.
New priorities include strengthening global quality and visibility, expanding education and training, and extending the partnership with the University of Antwerp to foster innovation.
Pharma.Aero remains well positioned for future success, confident in its ability to continue building momentum through industry collaboration and sustainable, high-quality outcomes.
Risk Factors
No negative points or risks could be extracted from this article as it exclusively reports on positive leadership transitions, organizational growth, and strategic expansion without mentioning any downsides.
Zoetis Inc., the largest animal health company globally, reported first-quarter 2026 results that missed analyst expectations, causing its stock to drop approximately 13% in premarket trading. The core issue driving the decline was a significant drop in U.S. sales, which fell 4% sequentially and 7% year over year to reach $2.3 billion for the quarter. This underperformance contrasts with revenue growth of roughly 5% in comparable international markets and 18% in the EMEA region. Consequently, Zoetis announced a reduction to its full-year guidance, which now reflects an adjusted diluted earnings per share range between $2.60 and $2.70, down from a previously anticipated range of $2.84 to $3.14.
Management attributed the weak U.S. performance to specific headwinds rather than broader structural issues. These challenges included lower usage of their veterinary medicines due to depressed animal populations caused by extreme weather events and an unfavorable shift in the distribution channel mix, specifically a decline in retail pet store sales which now account for roughly 47% of total revenue compared to 52% a year ago. Additionally, pricing pressures in the U.S. market remain intense due to heightened competition from generic products, particularly in the flea-and-tick and heartworm segments where Zoetis has faced increased pressure since recent acquisitions like Boehringer Ingelheim's animal health unit.
Despite the short-term guidance cut for fiscal 2026, the company reaffirmed its expectation that its international business will continue to grow at a rate of approximately 10% through at least 2030. The leadership noted that while U.S. pricing pressures are expected to persist throughout 2026 with an estimated average selling price decline of 2% to 3% compared to 2025, they remain confident in their portfolio's long-term resilience. Investors are now focusing on how Zoetis will navigate the ongoing competition from generic formulations and whether its international growth engine can offset continued stagnation in the domestic market.
๐ Zoetis shares fell 13% premarket after missing U.S. sales targets.
Zoetis, the animal health company listed under ticker ZTS, issued a downward revision to its full-year financial guidance following a disappointing first quarter performance that fell below analyst expectations. The stock price dropped approximately 7.8% in premarket trading and has declined about one-third of its value over the past year. CEO Kristin Peck attributed the challenges primarily to increased price sensitivity among pet owners, which led to reduced veterinary visits and weaker demand for premium innovative products, alongside intensified competition in key pet care categories.
In its updated outlook, Zoetis lowered its full-year earnings guidance to between $6.35 and $6.50 per share on a reported basis and $6.85 to $7.00 per share adjusted, down from previously expected ranges of $6.65 to $6.75 and $7.00 to $7.10 respectively. The company also reduced its revenue forecast to a range of $9.68 billion to $9.96 billion, decreasing from prior estimates of $9.83 billion to $10.03 billion. For the first quarter specifically, Zoetis reported net income of $601 million compared to $602 million in the year-ago period, with adjusted earnings of $1.53 per share missing the $1.60 consensus estimate.
While quarterly revenue grew 2.9% year-over-year to $2.26 billion, it still came in below the $2.3 billion analysts had predicted. In response to the challenging quarter, Peck stated the company intends to take decisive actions to improve execution, unlock revenue, and drive cost management moving forward. The article notes that Zoetis has seen sustained pressure on sales as consumer spending habits shift toward more budget-conscious choices in the pet care sector.
๐ Shares fell 7.8% as Zoetis cut full-year earnings and revenue guidance.
๐ธ Q1 revenue missed consensus while adjusted earnings per share were lower than expected.
๐พ CEO cites pet price sensitivity, competition, and declining veterinary visits for the decline.
๐ Zoetis shares fell 7.8% in premarket trading to $102.50 after the company cut its full-year outlook.
๐ธ Over the past year, the stock has lost approximately one-third of its value through Wednesday's close.
๐ First-quarter earnings were $601 million, a slight decrease from $602 million in the prior year.
๐ง Adjusted first-quarter earnings of $1.53 per share missed Wall Street models that expected $1.60.
๐ Q1 revenue rose 2.9% to $2.26 billion but came in short of the $2.3 billion analyst consensus.
๐ฌ CEO Kristin Peck attributed the weak performance to increased pet owner price sensitivity and intense competition.
๐พ Peck noted a decline in veterinary visits and softer demand for premium innovative pet products.
โก Management plans to take decisive actions to sharpen execution, unlock revenue, and drive cost management.
๐ฏ Zoetis now expects full-year earnings between $6.35 and $6.50 per share on a GAAP basis.
๐ต On an adjusted basis, the company projects annual earnings of $6.85 to $7 per share.
๐ This represents a downgrade from the previous guidance of $6.65 to $6.75 in GAAP earnings.
๐ Previously, the company had guided for adjusted earnings between $7 and $7.10 per share.
๐ฐ The new full-year revenue forecast ranges from $9.68 billion to $9.96 billion.
๐ This is a revision down from the prior view of $9.83 billion to $10.03 billion for annual revenue.
โ ๏ธ The outlook cuts reflect a challenging first quarter that exceeded expectations in both earnings and revenue misses.
Bullish Signals
Zoetis sharpens execution and drives cost management.
Revenue climbed 2.9% YoY to $2.26 billion.
Risk Factors
Zoetis cut full-year guidance to $6.35-$6.50 from $6.65-$6.75.
Revenue projections lowered to $9.68B-$9.96B from prior $9.83B-$10.03B.
Q1 earnings dropped slightly to $601M vs $602M last year.
Adjusted Q1 EPS of $1.53 missed Wall Street's $1.60 target.
Q1 revenue of $2.26B missed the $2.3B consensus estimate.
Shares fell 7.8% premarket and lost one-third value in a year.
Bullish Signals
Zoetis plans to take decisive actions moving forward to sharpen execution, unlock revenue, and drive cost management.
Despite the challenging quarter, revenue still climbed 2.9% year-over-year to $2.26 billion.
Risk Factors
Zoetis cut its full-year earnings guidance to $6.35-$6.50 per share, down from a previous expectation of $6.65-$6.75.
The company lowered revenue projections to between $9.68 billion and $9.96 billion, a decline from the prior view of $9.83 billion-$10.03 billion.
First-quarter earnings dropped slightly to $601 million compared to $602 million in the same quarter last year.
Adjusted quarterly earnings of $1.53 per share fell below Wall Street analyst models which projected $1.60 per share.
Revenue for the first quarter of $2.26 billion missed the $2.3 billion consensus estimate despite a year-over-year increase.
Shares experienced significant declines, falling 7.8% in premarket trading and losing about one-third of their value over the past year.
The animal health sector faces headwinds including increased price sensitivity among pet owners, reduced veterinary visits, and softer demand for premium products.
Zoetis Inc. (ZTS) shares experienced a significant selloff, plunging approximately 20% to close at $88.94 on Thursday, marking the weakest performance for any S&P 500 constituent that day and driving year-to-date losses to 29%. The sharp decline followed the company's first-quarter 2026 earnings report, which fell short of analyst expectations across key metrics. Reported quarterly earnings per share were $1.53, missing the Street consensus of $1.60, while sales reached $2.26 billion against a forecast of $2.3 billion. In response to the weaker-than-anticipated results, management cut its full-year 2026 EPS guidance range from $7.00-$7.10 to $6.85-$7.00 and revised revenue projections downward from $9.825-$10.025 billion to $9.68-$9.96 billion.
Chief Executive Kristin Peck attributed the poor performance to challenging market conditions, specifically noting rising consumer cost consciousness that reduced veterinary appointments and dampened demand for higher-priced offerings. Domestic sales declined by approximately 8% year-over-year, with the U.S. companion animal category dropping 11% due to weakening demand and increased competition. Conversely, international operations grew 17% year-over-year to $1.1 billion, largely supported by a parasiticides product line and a 10% increase in companion animal product revenue. However, this international growth was partially inflated by a non-recurring $100 million timing benefit resulting from a fiscal calendar adjustment that accelerated revenue recognition; Stifel analyst Jonathan Block noted that after accounting for this one-time boost, core operational performance was materially weaker than initial headlines suggested.
Looking ahead, Zoetis stated it is implementing "decisive action" to improve commercial execution, unlock revenue, and maintain disciplined cost management as consumer reluctance continues to press on the sector. The stock's valuation has dropped to levels last seen in early 2019 following Thursday's price action. Analysts from Stifel highlighted that underlying weakness, particularly in the pet care division, is more concerning than the headline numbers after adjusting for the one-time revenue acceleration. This marks a significant shift from Zoetis' previous reputation as a reliable growth story in the animal healthcare sector, with the company now facing heightened scrutiny on its domestic demand and future guidance execution.
๐ Zoetis shares plunged 20% as earnings and sales missed analyst expectations.
๐ Domestic revenue fell 8% due to weak consumer demand, masking international growth.
โฌ๏ธ CEO attributes the drop to cost consciousness and fewer vet appointments.
๐ Zoetis (ZTS) shares plunged 20% to $88.94 on Thursday, becoming the worst-performing stock in the S&P 500 for the day.
๐ธ First-quarter earnings per share of $1.53 missed the Street forecast of $1.60 despite year-over-year growth.
๐ Reported sales of $2.26 billion fell short of analyst expectations around $2.3 billion.
๐ The full-year 2026 EPS guidance was reduced to a range of $6.85โ$7.00 from the prior $7.00โ$7.10 projection.
๐ Domestic sales declined approximately 8% year-over-year, with companion animal revenue dropping 11% due to weak consumer demand.
๐ International operations grew 17% year-over-year to $1.1 billion, but included a non-recurring $100 million accounting timing benefit.
๐ Analysts from Stifel note that underlying operational performance is weaker than the headline numbers suggest after removing the one-time boost.
๐ Chief Executive Kristin Peck attributed the downturn to rising consumer cost consciousness and a reduction in veterinary appointments.
๐ ๏ธ Management promised "decisive action" to sharpen commercial execution and continue disciplined cost management going forward.
โฌ๏ธ Full-year revenue guidance was trimmed to $9.68โ$9.96 billion, missing Wall Street consensus estimates near $9.89 billion.
๐ The stock's current price levels match lows not seen since early 2019.
๐ Year-to-date losses for Zoetis have now reached 29%.
Bullish Signals
Zoetis EPS rose 9% year-over-year to $1.53.
International revenue surged 17% to $1.1 billion.
Parasiticides product line drove significant international expansion.
CEO Kristin Peck confirms decisive action for execution.
Risk Factors
Shares plunged 20% to $88.94, worst S&P 500 performer.
Earnings of $1.53 missed the $1.60 forecast by $0.07.
Domestic sales fell 8% to $1.1 billion amid weak spending.
Companion animal category dropped 11% due to intense competition.
Management warned of headwinds including rising consumer cost consciousness.
International growth of 17% masked by non-recurring revenue.
Full-year EPS outlook cut to $6.85โ$7.00 from $7.00โ$7.10.
Revenue guidance lowered to $9.68Bโ$9.96B below prior expectations.
Stock down 29% year-to-date, near early 2019 levels.
Bullish Signals
Zoetis adjusted earnings per share of $1.53 represented approximately 9% annual growth from the prior year's $1.48.
International operations delivered strong 17% year-over-year growth to reach $1.1 billion, supported by a 10% increase in companion animal product revenue.
The parasiticides product line contributed significantly to international expansion during the quarter.
Chief Executive Kristin Peck confirmed the company is implementing decisive action to sharpen commercial execution and continue to drive disciplined cost management.
Earnings beat year-over-year expectations despite missing analyst consensus by $0.07 per share.
Risk Factors
Zoetis shares plunged 20% to $88.94 on Thursday, marking the weakest performance among all S&P 500 constituents for the day.
First-quarter earnings of $1.53 per share missed the $1.60 Street forecast by $0.07, and sales of $2.26B trailed the $2.3B expectation.
Domestic sales declined approximately 8% year-over-year to $1.1 billion, driven by consumer reluctance to spend on pet care.
The companion animal category in the United States experienced an 11% drop due to weakening demand and intensified competitive dynamics.
Management warned of significant headwinds including rising consumer cost consciousness and a decline in veterinary appointments.
International growth of 17% included approximately $100 million in non-recurring revenue from a fiscal calendar adjustment, which masks weaker underlying performance.
The company reduced its full-year EPS outlook to $6.85โ$7.00 from the previous range of $7.00โ$7.10 due to challenging market conditions.
Full-year revenue projections were trimmed to a range of $9.68 billion to $9.96 billion, below the prior guidance of $9.825 billion to $10.025 billion.
The stock has suffered 29% losses year-to-date, trading at price levels not seen since early 2019.
Wall Street analysts have revised their earnings expectations for Zoetis Inc. (ZTS), anticipating a quarterly earnings per share (EPS) of $1.61, which represents an 8.8% year-over-year increase. Revenue estimates stand at $2.3 billion, suggesting a 3.6% growth compared to the previous quarter. Over the last 30 days, the consensus EPS estimate has been adjusted upward by 1.1%, reflecting positive sentiment among covering analysts who are reassessing their initial projections ahead of the upcoming earnings release.
Breaking down revenue expectations by segment, analysts project that companion animal revenues will reach $1.58 billion with a 2.3% increase, while livestock revenues are expected to hit $680.48 million, growing by 5.5%. Within the livestock sector, international performance looks particularly strong, with projections showing significant growth in global livestock revenue (+7%) and international companion animal sales (+6.4%), whereas U.S. companion animal revenue is expected to remain relatively flat at +0.4%. Geographic splits indicate a robust outlook for international revenues overall ($1.08 billion) compared to the U.S. market ($1.20 billion).
Despite these positive fundamental indicators, Zoetis shares have underperformed the broader market recently, dropping -4.7% over the past month while the Zacks S&P 500 composite rose 9.5%. Consequently, analysts maintain a Zacks Rank #3 (Hold) for the stock, suggesting that its future performance may align more closely with overall market trends in the coming period rather than significantly outperforming or underperforming immediately based on the current projections.
๐ Analysts project quarterly EPS of $1.61 and revenue growth of 3.6% to $2.3 billion.
๐ International segment leads with 6.7% growth while U.S. sees modest gains across segments.
โ๏ธ Shares are down 4.7% monthly; Zacks rates the stock as a Hold (Rank #3).
๐ Wall Street analysts expect Zoetis (ZTS) to report quarterly earnings of $1.61 per share, representing an 8.8% increase from the previous year.
๐ฐ Projected revenue for the quarter is set at $2.3 billion, which would reflect a 3.6% growth compared to the same period last year.
๐ The consensus EPS estimate has been adjusted upward by 1.1% over the past 30 days, indicating positive reassessment by covering analysts.
๐ฌ Revenue from contract manufacturing and human health is estimated at $28.94 million with a negligible decline of -0.2% year-over-year.
๐พ Companion animal revenue is projected to reach $1.58 billion, showing a 2.3% increase from the prior-year quarter.
๐ Livestock sector revenues are estimated at $680.48 million, reflecting a 5.5% growth year-over-year.
๐ Swine-specific revenue within livestock is forecasted to be $112.11 million, marking a 1% increase from the previous quarter.
๐ Cattle segment revenues are expected to hit $370.52 million, indicating a 3.5% rise year-over-year.
๐ Fish-related livestock revenue is projected at $57.00 million, showing a significant 7.6% jump from the prior year.
๐ U.S. geographic revenues are estimated at $1.20 billion, representing a 1.2% increase year-over-year.
๐ International revenues are forecasted to reach $1.08 billion, with a strong 6.7% growth rate compared to the previous year.
๐ U.S.-based livestock revenue is expected to arrive at $221.92 million, reflecting a 5.7% increase from the prior year.
๐พ U.S.-based companion animal revenue is projected at $976.53 million with a slight 0.4% rise year-over-year.
๐ Zoetis shares have declined by 4.7% over the past month, underperforming the S&P 500 composite which rose 9.5%.
โ๏ธ Zacks assigns Zoetis a Rank #3 (Hold), suggesting future performance will likely align with the overall market trend.
Bullish Signals
Analysts forecast Zoetis (ZTS) EPS at $1.61, an 8.8% increase.
Revenue expected to hit $2.3 billion, up 3.6% year-over-year.
EPS estimates rose 1.1% in the last 30 days.
Companion Animal revenue projected at $1.58 billion, up 2.3%.
Livestock segment shows $680.48M revenue growth of +5.5%.
International revenue expected to reach $1.08B, growing 6.7%.
Risk Factors
Shares underperformed with -4.7% return vs S&P 500's +9.5%.
Wall Street analysts expect Zoetis (ZTS) to post quarterly earnings of $1.61 per share, indicating an optimistic year-over-year increase of 8.8%.
Revenues are forecast to reach $2.3 billion, reflecting a positive growth trajectory of 3.6% compared to the prior-year quarter.
Analyst consensus for EPS estimates has been adjusted upward by 1.1% over the past 30 days, signaling growing investor confidence in the company's performance.
Companion Animal revenues are projected to reach $1.58 billion, with analysts estimating a solid year-over-year increase of 2.3%.
Livestock segment shows robust growth potential, with estimated revenues of $680.48 million and a strong year-over-year change of +5.5%.
International revenue is expected to grow significantly at +6.7% year over year, reaching $1.08 billion, highlighting expansion outside the U.S. market.
Risk Factors
Despite upward adjustments in consensus EPS estimates over the past 30 days, Zoetis shares have underperformed the broader market significantly, recording a -4.7% return versus the Zacks S&P 500 composite's +9.5% change.
The company currently holds a Zacks Rank #3 (Hold) rating, suggesting limited upside potential compared to top-rated stocks in the list.
Revenues from Contract Manufacturing & Human Health are projected to decline slightly by -0.2% year over year compared to the prior-year quarter.
U.S. Companion Animal revenues are expected to remain nearly flat with only a marginal +0.4% increase from the previous period.
Zoetis (ZTS) is attracting renewed investor interest due to optimistic expectations for its first quarter 2026 earnings scheduled for release on May 7, alongside recent developments regarding its Vetscan OptiCell AI-powered diagnostic platform. Despite this positive narrative and supportive analyst commentary, the stock has underperformed recently; it experienced a 2.74% decline over the past 30 days and is down 24.99% in total shareholder return over the last year. This divergence between product news and share price performance raises questions about whether current valuations already reflect future growth potential or if the stock remains undervalued despite fading momentum.
Simply Wall St's latest analysis suggests Zoetis may be significantly undervalued, estimating a fair value of $151 per share compared to a recent closing price of approximately $114.97. This valuation model is built using a 6.98% discount rate and assumes steady revenue expansion, improving profit margins, and a higher earnings base supported by ongoing innovation and accelerated R&D output. The thesis anticipates that Zoetis will see major new product approvals in key markets annually for the foreseeable future, which should help expand addressable markets, launch higher-margin products, and protect market share to positively impact organic revenue growth and net margins.
However, potential risks could challenge this upbeat outlook, including reported execution setbacks in key osteoarthritis products and intensifying competition within parasiticides and dermatology segments. While the analysis spreads expectations across the existing portfolio, new launches, and international growth rather than relying on a single product or region, it acknowledges that competitive dynamics and execution issues could impact the overall thesis. The article notes that mixed signals exist across valuation metrics, product performance, and share price trends, prompting investors to examine underlying data regarding income streams, value opportunities, and balance sheet strength before making investment decisions. The content is presented as general analysis based on historical data and analyst forecasts rather than specific financial advice.
๐ค The new AI-powered OptiCell platform is drawing significant investor attention.
๐ฐ Analysts value the stock at $151, marking it as potentially undervalued.
๐ Zoetis (ZTS) has seen its share price weaken over the past year, posting a 24.99% total shareholder return decline despite positive market sentiment.
๐ Investors are awaiting upcoming first-quarter earnings on May 7 with high expectations driven by recent product and AI news.
๐ค The company's Vetscan OptiCell platform is receiving fresh attention due to its integration of AI-powered diagnostics capabilities.
๐ Financial analysis models currently suggest a fair value of $151, which is significantly higher than the latest closing price of $114.97.
๐ฎ This valuation gap implies the stock may be undervalued based on assumptions of sustained revenue growth and rising profit margins.
๐ก The valuation narrative relies on a 6.98% discount rate and spreads expectations across existing products, new launches, and international markets.
๐ Management anticipates major new product approvals in key markets annually over the next few years to support organic growth.
โ ๏ธ Potential risks include execution setbacks in osteoarthritis products and increasing competition in parasiticides and dermatology segments.
๐ Simply Wall St identifies five key rewards and one important warning sign for investors considering this healthcare stock.
๐ก๏ธ Broader investment considerations such as dividend stability, balance sheet strength, and undervaluation metrics are also highlighted.
Bullish Signals
Fair value analysis suggests Zoetis is currently undervalued at $114.97 compared to a model-derived target price of $151.
Investors hold upbeat expectations for the upcoming first quarter 2026 earnings release scheduled for May 7.
Ongoing innovation and accelerated R&D output are positioning the company for major new product approvals in key markets every year over the next few years.
The valuation narrative assumes steady revenue expansion, improving profit margins, and a higher earnings base to support sustained growth.
Zoetis aims to expand its addressable market, launch higher-margin products, and protect market share through its diversified portfolio.
Fair value estimates are built on a robust 6.98% discount rate that accounts for the existing portfolio, new launches, and international growth.
Risk Factors
Despite upbeat analyst expectations and positive AI diagnostics news, Zoetis has underperformed with a 24.99% decline in its 1-year total shareholder return.
The stock's recent momentum is fading, evidenced by a 2.74% share price decline over the past 30 days despite May 7 earnings optimism.
A fair value analysis suggests Zoetis may be undervalued at $151 compared to a close of $114.97, but this relies on assumptions that could prove overly optimistic if execution falters.
Specific downside risks include potential execution setbacks in key osteoarthritis products which could challenge the upbeat growth narrative.
Rising competition is anticipated in crucial segments such as parasiticides and dermatology, threatening market share and margin expansion plans.
The valuation model assumes a steady revenue expansion and improving profit margins using a 6.98% discount rate, creating vulnerability if these fundamental drivers falter.
Shares of Zoetis Inc. (ZTS) increased by 1.00% to reach $114.97 on Thursday, marking a recovery that ended a two-day losing streak for the stock. This positive movement occurred during a broader rally in the market, where the S&P 500 Index rose 1.02% to 7,209.01 and the Dow Jones Industrial Average advanced 1.62% to 49,652.14. Despite this intraday gain, Zoetis stock continues to underperform the wider market indices, having failed to match the stronger gains seen by the major benchmarks during the session.
The article notes that the trading session overall was favorable for equity markets, providing a supportive backdrop for individual stocks like ZTS. However, even with this improvement in performance on Thursday, Zoetis remains behind the pace set by the broader market indices. This divergence suggests that while investor sentiment may be improving for the pharmaceutical and veterinary medicine sector specifically, Zoetis has not yet fully regained the relative momentum it held prior to its recent losses or the gains experienced by the S&P 500 and Dow Jones over the same period.
๐บ Zoetis shares rose 1.00% to close at $114.97 Thursday.
๐ The stock ended a two-day losing streak despite underperformance.
๐ Major indices S&P 500 and Dow Jones posted strong gains.
๐ Zoetis Inc. (ZTS) shares advanced 1.00% to close at $114.97 on Thursday.
๐ The stock market saw a strong session with the S&P 500 rising 1.02% and the Dow Jones rising 1.62%.
๐ This price increase ended a two-day losing streak for the company's stock.
โ๏ธ Despite the gain, Zoetis still underperformed the broader market indices in this trading session.
๐ Closing data reflects an all-around positive trend across major U.S. stock benchmarks.
Bullish Signals
Zoetis Inc. (ZTS) shares advanced 1.00% to $114.97, continuing a positive trading trend despite broader market underperformance.
The stock's rise successfully snapped a two-day losing streak, demonstrating resilience and potential for recovery.
Zoetis performed in an all-around great trading session alongside major indices like the S&P 500 and Dow Jones Industrial Average.
Risk Factors
Zoetis Inc. (ZTS) stock continues to underperform the broader market despite a recent rise, with ZTS up only 1.00% compared to the S&P 500 rising 1.02% and the Dow Jones Industrial Average surging 1.62%.
Shares of Zoetis had experienced a two-day losing streak prior to Thursday's recovery, indicating recent downward pressure or negative sentiment.
Zoetis Inc. (ZTS) shares closed lower at $113.35, marking a 2.81% decline for the day and outpacing the broader market's negative momentum, which saw the S&P 500 drop 1.67%, the Dow fall 1.73%, and the Nasdaq lose 2.15%. Over the past month, ZTS stock had already underperformed by 10.12%, compared to a 7.36% loss for the Medical sector and a 6.15% loss for the S&P 500. Investors are now closely watching the company's upcoming earnings release, which has generated significant interest following this recent price weakness.
Analyst expectations for Zoetis remain positive despite the stock's short-term downturn, with projected quarterly earnings of $1.61 per share, representing an 8.78% increase year-over-year. Revenue is forecasted to reach $2.32 billion, indicating a 4.58% growth compared to the prior quarter's figures. Full-year estimates from Zacks Consensus suggest earnings of $6.99 per share and revenue of $9.91 billion, reflecting projected changes of +9.05% and +4.66% respectively from last year. Recent revisions to these analyst forecasts are being monitored closely as they often correlate with impending stock price performance according to empirical research.
Valuation metrics indicate Zoetis is trading at a Forward P/E ratio of 16.69, which suggests a discount compared to the industry average of 17.97. The company also has a PEG ratio of 1.79, whereas the Medical - Drugs industry average stands at 1.24. Industry analysis places Zoetis within a sector ranked in the top 41% of all industries by the Zacks Industry Rank system, which assesses group vigor based on individual stock rankings and shows that top-rated industries outperform the bottom half by a factor of 2 to 1.
Currently, Zoetis holds a Zacks Rank of #2 (Buy), while its Consensus EPS estimate has seen a slight rise of 0.06% over the past month. Historically, the Zacks Rank system from Zacks Investment Research has delivered strong performance, with #1 stocks posting an average annual return of +25% since 1988 based on outside-audited data. The article concludes by directing investors to monitor stock-impacting metrics such as analyst revisions and industry ranks via Zacks.com and offers a downloadable report of top picks for the next 30 days.
๐ Zoetis shares fell 10.12% this month, lagging behind market and sector declines.
๐ฐ Forecast earnings grow 8.78% YoY to $1.61 with revenue reaching $2.32 billion.
๐ต The stock trades at a discounted Forward P/E of 16.69 versus the industry average.
๐ Zoetis (ZTS) shares closed down 2.81% at $113.35, underperforming the S&P 500's 1.67% loss and other major market indices.
๐ Over the past month, ZTS shares have declined 10.12%, trailing the broader Medical sector's drop of 7.36% and the S&P 500's 6.15% decline.
๐ Investors are closely watching Zoetis' upcoming earnings release, with consensus EPS estimates projected at $1.61, reflecting an 8.78% year-over-year increase.
๐ฐ Revenue forecasts for the upcoming quarter stand at $2.32 billion, indicating a 4.58% growth compared to the corresponding quarter last year.
๐ฎ Full-year consensus estimates anticipate earnings of $6.99 per share and revenue of $9.91 billion, both representing modest double-digit growth over the prior year.
โ ๏ธ Analyst forecast revisions can signal future stock performance, with positive changes suggesting optimism regarding business trends and profitability.
๐ Zoetis currently holds a Zacks Rank of #2 (Buy), having seen a 0.06% rise in its consensus EPS estimate over the past month.
๐ต The company trades at a Forward P/E ratio of 16.69, which is lower than the industry average of 17.97, suggesting a potential valuation discount.
๐ Zoetis has a PEG ratio of 1.79, factoring in expected earnings growth, compared to an industry medical drugs average of 1.24.
๐ญ The Medical - Drugs industry holds a Zacks Industry Rank of 99, placing it in the top 41% out of all tracked industries.
๐ Historical data indicates that high-performing industries tend to significantly outperform the bottom half by a factor of 2 to 1.
Bullish Signals
Zoetis' upcoming quarterly earnings are projected to reach $1.61 per share, representing an 8.78% increase over the same quarter last year.
Revenue is forecast at $2.32 billion, which indicates a 4.58% growth compared to the corresponding quarter of the prior year.
Full-year Zacks Consensus Estimates suggest earnings of $6.99 per share and revenue of $9.91 billion, both marking positive changes of +9.05% and +4.66% respectively from last year.
The Zacks Rank for Zoetis is #2 (Buy), with #1 ranked stocks delivering an average annual return of +25% since 1988.
Zoetis is currently trading at a Forward P/E ratio of 16.69, which is below the industry average Forward P/E of 17.97, suggesting a valuation discount.
The Medical - Drugs industry has a Zacks Industry Rank of 99, placing it in the top 41% of all 250+ industries, indicating strong relative performance potential.
Risk Factors
Zoetis stock price fell -2.81% recently, outperforming the market decline more negatively as it underperformed the S&P 500 (down 1.67%) and Nasdaq (down 2.15%).
Shares had already lost 10.12% in the past month compared to only a 6.15% drop for the broader S&P 500, indicating relative weakness.
The PEG ratio of 1.79 is significantly higher than the industry average of 1.24, potentially suggesting overvaluation relative to its expected earnings growth.
Zoetis trades at a Forward P/E of 16.69 which is slightly lower than the industry average of 17.97, but investors should remain cautious given recent momentum.
Zoetis Inc. (ZTS) shares declined 2.81% to $113.35 on Friday, March 27, 2026, continuing a streak of losses that marks the company's second consecutive day of negative trading performance. This underperformance occurred amid a broader downturn in the stock market, characterized as an "all-around grim trading session" where major indices also fell significantly. Specifically, the S&P 500 Index (SPX) dropped 1.67% to close at 6,368.85, while the Dow Jones Industrial Average (DJIA) experienced a decline of 1.73%, settling at 45,166.64. The data for Zoetis's price action reflects intraday trading information provided by FACTSET and Nasdaq reports.
The summary indicates that this specific decline in ZTS shares was part of the general market weakness rather than an isolated event for the company. Despite the stock's slide relative to the broader context, no specific commentary on competitors was included in the provided text to clarify whether Zoetis significantly underperformed them or merely followed the market trend more closely during this particular session. The reporting is attributed to MarketWatch Automation, which notes that the data provided is subject to terms of use and reflects real-time last sale data for U.S. stock quotes.
Overall, the article highlights the specific price movement of Zoetis on March 27, 2026, framing it within the context of a challenging trading day across major market benchmarks. The publication date is noted as March 27, 2026, at 4:50 p.m. ET, with the copyright belonging to MarketWatch, Inc., which also includes standard disclaimers regarding delayed data and exchange requirements for the quotes presented.
๐ Zoetis shares fell 2.81% to $113.35 amid market drops.
โ ๏ธ The stock recorded losses for two consecutive days.
๐ข Data sourced from MarketWatch, Dow Jones, and FactSet.
๐ Zoetis Inc. (ZTS) shares dropped 2.81% to $113.35 on Friday amid a broadly negative market session.
๐ The S&P 500 Index fell 1.67% to 6,368.85 while the Dow Jones Industrial Average declined 1.73% to 45,166.64.
โ ๏ธ This price decline marked Zoetis's second consecutive day of losses for the stock.
๐ข MarketWatch provided the reporting with data support from Dow Jones, FactSet, and Automated Insights.
โ๏ธ The article notes the stock underperformed relative to its competitors on Friday.
Bullish Signals
Risk Factors
Zoetis Inc. (ZTS) shares slid 2.81% to $113.35 Friday, continuing a second consecutive day of losses.
ZTS underperformed competitors during an already grim trading session where the broader market faced significant declines.
Zoetis Inc. (NYSE:ZTS) is identified as a high-quality dividend stock suitable for income-focused investors seeking dependable payouts backed by strong fundamentals. The company, the global leader in animal health, received a ChartMill Dividend Rating of 7, a Profitability Rating of 9, and a Health Rating of 6, indicating a profile that prioritizes safety and quality over maximizing yield.
The article highlights Zoetis's robust financial foundation, noting an almost perfect profitability rating that supports its shareholder payments. While the company carries a Debt-to-Equity ratio of 2.71, this leverage is viewed as purposeful for improving returns rather than a risk, as it is offset by powerful cash creation capabilities that ensure dividend safety and provide flexibility to manage debt obligations.
From a valuation perspective, Zoetis trades at a P/E ratio near 18, which is considered low compared to both its historical averages and the wider pharmaceuticals industry. Analysts forecast moderate future growth with mid-single-digit revenue expansion and high-single-digit EPS growth in the coming years, providing a solid basis for potential future dividend raises.
๐ Zoetis holds a top-tier ChartMill Dividend Rating of 7.
๐ฐ Exceptional Profitability Rating of 9 backs strong dividends.
โ๏ธ Manages 2.71 debt-to-equity ratio via powerful cash creation.
๐ Trades at P/E near 18, below historical and industry averages.
๐ Analysts forecast mid-single-digit revenue and high-single-digit EPS growth.
๐ Zoetis Inc. (NYSE:ZTS) is highlighted as a top global animal health company with a ChartMill Dividend Rating of 7.
๐ฐ The company boasts an exceptional Profitability Rating of 9, ensuring dividends are backed by strong financial results.
โ๏ธ Despite a Debt-to-Equity ratio of 2.71, the firm manages debt effectively through powerful cash creation and purposeful leverage.
๐ Zoetis trades at a P/E ratio near 18, which is lower than its historical averages and the broader pharmaceuticals industry.
๐ Analysts forecast mid-single-digit revenue growth and high-single-digit EPS growth for the next few years.
๐ก๏ธ The company generates strong returns on invested capital and free cash flow relative to its market price.
๐ Zoetis operates in a stable, less cyclical segment of the market with established financial strength characteristics.
Bullish Signals
Exceptional Profitability Rating of 9 supported by strong earnings.
P/E ratio near 18 is undervalued versus history and peers.
Analysts predict mid-single-digit revenue and high-single-digit EPS growth.
Strong returns on invested capital drive efficient shareholder value.
Strong free cash flow provides ample liquidity for dividends.
Bullish Signals
Zoetis has an exceptional Profitability Rating of 9, indicating that its dividends are well-supported by strong earnings and cash generation.
The company trades at a P/E ratio near 18, which is undervalued compared to both its own history and the wider pharmaceuticals industry.
Analysts predict continued moderate growth with mid-single-digit revenue expansion and high-single-digit EPS growth in the coming years.
Zoetis generates strong returns on invested capital, demonstrating efficient use of resources to drive shareholder value.
The company produces strong free cash flow relative to its market price, providing ample liquidity for operations and dividends.
Zoetis belongs to a stable, less cyclical segment of the market, offering lower volatility compared to other sectors.
Zoetis Inc. (ZTS) is adjusting its product strategy to address shifting veterinary care dynamics where routine visits are slowing but spending per visit has increased by 6%. CEO Kristin Peck highlighted that the company's blockbuster dermatology drug, Apoquel, faces unprecedented competitive pressure from cheaper generic pills flooding the market. To counter this, Zoetis is pivoting toward long-acting injectables like Cytopoint, which eliminate monthly visit fees and improve medical compliance for pet owners by removing the need for daily pill administration.
The company's livestock division is experiencing mid-to-high single-digit growth, a significant acceleration from its historical 2% to 4% annual rate. Peck attributes this surge to the global impact of GLP-1 weight-loss drugs, which cause patients to consume more animal protein to preserve muscle mass, thereby driving demand for healthy poultry, cattle, and pork. Despite Wall Street's current focus on generic competition and a recent 32.20% stock drawdown, management emphasizes that the current share price fails to reflect the future of chronic animal care.
Zoetis is leveraging its proprietary animal genetics database and artificial intelligence to develop high-margin therapies for aging pets, specifically targeting the 'COVID puppies' cohort entering their senior years with cancer and organ failure needs. The company expects a revolutionary kidney disease drug approval in 2027 that targets a $3 billion to $4 billion unmet market need, currently lacking any preventative products for early-stage renal damage in dogs and cats. This pipeline is designed to offset the patent cliff on Apoquel and capitalize on the growing demand for specialized chronic care.
Analysts using TIKR's Valuation Model project a $166.98 target price based on a conservative 4.3% Revenue CAGR through 2031, which aligns with management's organic growth guidance. The model forecasts a staggering 30.9% Net Income Margin and an 8.0% annualized IRR for long-term investors, driven by the lower manufacturing costs of injectables compared to daily pills and premium pricing on monoclonal antibody therapies. Ultimately, Zoetis is positioned to outgrow short-term headwinds through its booming livestock segment and a robust AI-driven pipeline addressing billion-dollar unmet needs.
๐ Spending per visit jumped 6% despite fewer routine visits.
๐ Apoquel faces pressure from cheaper generic pill competition.
๐ Zoetis pushes 3-month injectables to improve medical compliance.
๐ Livestock division grew mid-to-high single-digits vs historical 2-4%.
๐ค AI selects drug molecules with fewer side effects than traditional methods.
๐ Total spending per veterinary clinic visit recently jumped by 6%, indicating pet owners are willing to pay for premium, specialized care despite fewer routine visits.
๐ CEO Kristin Peck stated that Apoquel faces unprecedented competitive pressure from cheaper generic pills flooding the market.
๐ Zoetis is pushing 3-month, long-acting injectables like Cytopoint to eliminate monthly vet visit fees and improve medical compliance for pet owners.
๐ The livestock division is posting mid-to-high single-digit growth, historically growing only 2% to 4% annually.
๐ฅฉ Peck linked the global surge in livestock demand directly to GLP-1 weight-loss drugs causing patients to consume more animal protein to preserve muscle mass.
๐ The stock suffered a severe 32.20% max drawdown earlier this year due to Wall Street's obsession with generic dermatology threats.
๐ค Zoetis is using artificial intelligence and its proprietary animal genetics database to select drug molecules with fewer side effects than traditional research methods.
๐ฅ Management expects a revolutionary kidney disease drug approval in 2027 targeting a $3 billion to $4 billion Total Addressable Market for early-stage renal damage.
๐ The TIKR Advanced Model projects a $166.98 target price relying on a conservative 4.3% Revenue CAGR through 2031.
๐ฐ The model forecasts a staggering 30.9% Net Income Margin and an 8.0% annualized IRR for long-term investors.
Bullish Signals
Spending per visit jumped 6% as owners pay for premium care.
Livestock division growth outpaces historical 2% to 4% annual rate.
Injectables improve compliance and reduce monthly fees for pet owners.
AI genetics database selects molecules with fewer side effects than traditional methods.
$3B-$4B kidney drug targets massive unmet market need by 2031.
TIKR model projects $166.98 target price on 4.3% Revenue CAGR.
Model forecasts staggering 30.9% Net Income Margin highlighting profitability.
Injectables manufacturing costs less than pills, improving margins significantly.
Risk Factors
Apoquel faces generic competition flooding the market.
Routine vet visits are slowing industry-wide.
Stock suffered a 32.20% max drawdown earlier this year.
Current $115.67 price may not reflect future potential.
Bullish Signals
Total spending per clinic visit recently jumped by 6%, proving pet owners are still willing to pay for premium, specialized care.
The livestock division is booming with mid-to-high single-digit growth, significantly outpacing its historical 2% to 4% annual growth rate.
Zoetis is successfully transitioning to long-acting injectables like Cytopoint that improve medical compliance and reduce monthly visit fees for pet owners.
The company's AI-driven approach using a massive proprietary animal genetics database allows it to select drug molecules with far fewer side effects than traditional methods.
A revolutionary kidney disease drug is expected to receive approval in 2027, targeting a massive $3 billion to $4 billion unmet market need.
The TIKR Advanced Model projects a $166.98 target price based on a conservative 4.3% Revenue CAGR through 2031 that matches management's guidance.
The model forecasts a staggering 30.9% Net Income Margin, highlighting the company's incredible profitability and defensive nature.
Long-acting injectables cost much less to manufacture at scale than millions of daily pills, improving margins significantly.
Risk Factors
The company's blockbuster dermatology drug, Apoquel, faces unprecedented competitive pressure from cheaper generic pills currently flooding the market.
Routine veterinary visits are slowing down across the industry, potentially impacting overall clinic foot traffic.
Wall Street is currently fixated on generic competition and slow clinic traffic, causing the stock to suffer a severe 32.20% max drawdown earlier this year.
The current share price of $115.67 may not accurately reflect the future potential of chronic animal care due to market pessimism.
Diamond Hill Capital released its fourth-quarter 2025 investor letter in March 2026, highlighting Zoetis Inc. (NYSE: ZTS) as one of its key selections within the Diamond Hill Mid Strategy portfolio. The firm noted that while large and small-cap equities posted favorable gains in Q4, with returns of 2.41% and 2.19% respectively, the mid-cap range was a relative laggard, with the Russell Mid Cap Index returning only 0.16%. Despite this broader market context, the Diamond Hill Mid Strategy returned 3.65% net in Q4, significantly outperforming the index, and posted a year-to-date return of 13.47% compared to the Russell Midcap Index's 10.60%.
The strategy manager expressed bullish views on Zoetis, describing it as a market leader with products for both companion animals and livestock that offers multiple growth drivers and a strong pipeline for under-treated pet conditions. The firm indicated that recent share price pressure due to concerns over one of its arthritis drugs used in dogs created an opportunity to enter the position below the company's estimated intrinsic value. However, specific stock data points out a -5.77% return over the past month and a 25.69% decline over the past twelve months as of the March 17, 2026 closing price of $121.68 per share. The company maintains a market capitalization of approximately $53.624 billion.
While Diamond Hill Capital holds a position in Zoetis, they noted that the stock was not included in their list of the 40 Most Popular Stocks Among Hedge Funds heading into 2026. Data shows that hedge fund portfolios holding Zoetis decreased slightly to 69 at the end of Q4 2025 from 72 in the previous quarter. In its investor letter, Diamond Hill Capital stated that while they acknowledge the risk and potential of ZTS as an investment, their conviction lies with AI stocks, which they believe hold greater promise for delivering higher returns within a shorter time frame. The article also points readers toward additional resources, including Jensen Quality Growth Equity Strategy's views on the company and related articles discussing Zoetis's recent Q3 performance and other analyst ratings like Barclays maintaining a Hold position.
๐ฐ Fund returned 3.65% in Q4, significantly outpacing its benchmark index.
๐ Stock dropped 25.7% this year due to arthritis drug concerns.
๐ค Manager favors AI stocks over Zoetis for better short-term returns.
๐งฌ Company maintains a strong pipeline with multiple growth drivers.
๐ผ Diamond Hill views current prices as an undervalued entry opportunity.
๐ฐ Diamond Hill Mid Strategy returned 3.65% in Q4 2025, outperforming the Russell Mid Cap Index's 0.16%.
๐ฅ Zoetis is a leader in animal health with products for companion animals and livestock.
๐ The stock closed at $121.68 per share on March 17, 2026, down 5.77% in the past month.
โ ๏ธ Shares lost 25.69% over the past twelve months amid concerns about a specific dog arthritis drug.
๐ผ Diamond Hill views Zoetis as undervalued after recent price pressure created an entry opportunity.
๐งฌ The company has a broad portfolio with multiple growth drivers and a strong pipeline for undertreated pet conditions.
๐ 69 hedge fund portfolios held Zoetis at the end of Q4 2025, down slightly from 72 in the previous quarter.
๐ค Diamond Hill prioritizes AI stocks over Zoetis due to perceived higher return potential and shorter timeframes.
๐ซ Zoetis is not included on their list of 40 Most Popular Stocks for the upcoming year.
๐ The market capitalization of Zoetis is approximately $53.6 billion as of early March 2026.
Bullish Signals
Diamond Hill Capital's Mid Strategy holds Zoetis Inc. (NYSE: ZTS) as a top five holding, indicating strong institutional confidence in the company.
Zoetis is recognized as a leader in the animal health market with leading products for companion animals and livestock, offering multiple growth drivers.
The company has a broad portfolio with a strong pipeline designed to address several undertreated pet conditions, providing clear upside potential.
Recent share price pressure due to concerns about an arthritis drug has created an entry opportunity at below intrinsic value for the Strategy.
Zoetis maintains a substantial market capitalization of approximately $53.624 billion, demonstrating its established market position.
Risk Factors
Zoetis Inc. (NYSE: ZTS) stock closed at $121.68 per share, down -5.77% in the past month and losing 25.69% over the past twelve months.
Concerns about one of its arthritis drugs used in dogs have pressured the share price recently, indicating specific product-level headwinds.
Diamond Hill Mid Strategy is not recommending Zoetis as a top AI investment, stating that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame.
Zoetis Inc. (NYSE: ZTS) is not on the list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026, signaling a lack of institutional enthusiasm.
Hedge fund interest in Zoetis has declined to 69 portfolios holding the stock at the end of Q4 2025, down from 72 in the previous quarter.
Zoetis (ZTS) shares are trading at $125.93, nearly 29% below their 52-week high, despite the company beating Q4 revenue estimates by $27 million and acquiring Neogen's genomics business for $160 million on March 2. While certain franchises like Simparica, dermatology, and OA pain faced lighter-than-expected performance due to price sensitivity and new FDA-approved competition from Merck's Numelvi, Zoetis still delivered Q4 adjusted EPS of $1.48 against a $1.40 estimate.
The company is building a robust pipeline with 12 potential blockbusters in development, including CYTOPOINT long-acting approval expected late 2026 and Lenivia launching in EU and Canada in the first half of 2026. The Neogen acquisition reinforces Zoetis's precision animal health capabilities, aligning with analyst consensus for 4.7% revenue growth in 2026 as the business stabilizes following a turbulent year.
Fundamentally, revenue is projected to grow from $9.5 billion in 2025 to $9.9 billion in 2026, with normalized EPS accelerating 9.6% to $7.0. Zoetis generated $4.2 billion in EBITDA in 2025 at 44.8% margins, maintaining structural profitability despite competitive pressures. Management views the current valuation as disconnected from these fundamentals, citing a disconnect between performance and market price.
Analysts maintain a mean price target of $151.0, implying 19.9% upside, though targets range from $130 to $190 depending on the trajectory of Librela's decline and future approvals. A TIKR valuation model projects a target of $178.4 by December 31, 2030, suggesting a 41.7% total return and 7.5% annual IRR. The primary risk remains the potential spread of Librela's Q4 decline to the broader OA pain franchise.
๐ Stock down 29% from $177 high, trading at $125.93.
๐ฐ Q4 EPS beat estimates at $1.48 vs $1.40 consensus.
๐ Simparica franchise hit $1.5B revenue with 12% growth.
๐ Simparica Trio crossed $1B U.S. annual sales for first time.
โ ๏ธ Librela U.S. sales fell 32% in Q4 creating risk.
๐ ZTS stock trades at $125.93, down nearly 29% from its 52-week high of $177.00.
๐ฐ Q4 adjusted EPS beat estimates at $1.48 versus a consensus of $1.40.
๐ค Zoetis acquired Neogen's genomics business for $160 million on March 2 to expand precision capabilities.
๐ Simparica franchise generated $1.5 billion in 2025 revenue with 12% operational growth.
๐ Simparica Trio crossed $1 billion in U.S. annual sales for the first time.
โ ๏ธ Merck's Numelvi received FDA approval on February 25, intensifying dermatology competition.
๐ฌ CYTOPOINT long-acting approval is expected late 2026 to offset portfolio pressure.
๐ Lenivia is scheduled to launch in EU and Canada in the first half of 2026.
๐ Revenue projected to grow from $9.5B in 2025 to $9.9B in 2026.
๐น Normalized EPS expected to accelerate 9.6% to $7.0 in 2026.
๐ก๏ธ Livestock segment delivered 8% organic operational growth in 2025.
๐ EBITDA margins held steady at 44.8% in 2025 despite market headwinds.
๐ฅ Wall Street consensus includes 7 buys, 4 outperforms, and 9 holds.
๐ฏ Mean analyst price target is $151.0, implying 19.9% upside from current price.
๐ Librela U.S. sales declined 32% in Q4, posing a significant near-term risk.
๐ฎ TIKR model targets $178.4 by end of 2030 for a 41.7% total return.
๐ฃ๏ธ CEO Kristin Peck attributes recent softness to price sensitivity and tighter household budgets.
๐ CFO Wetteny Joseph highlighted a disconnect between business performance and current valuation.
Bullish Signals
Beat Q4 revenue estimates by $27M with $1.48 adjusted EPS.
Simparica franchise hit $1.5B 2025 revenue with 12% operational growth.
Livestock segment delivered strong 8% organic operational growth in 2025.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)